US Agency Broadens Coverage Of Personalis Breast Cancer Test
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Personalis to Participate in Upcoming Investor Events
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis Q1 Earnings Call Highlights
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis Reports First Quarter Results and Recent Highlights
Personalis to Announce First Quarter 2026 Financial Results
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Personalis, Inc. $PSNL Shares Acquired by Aberdeen Group plc
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Personalis to Participate in the 25th Annual Needham Virtual Conference
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of “Moderate Buy” from Analysts
Personalis, Inc. (NASDAQ:PSNL) Sees Large Increase in Short Interest
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
Personalis (NASDAQ:PSNL) Shares Down 4.8% – Time to Sell?
Personalis (PSNL) to Release Earnings on Thursday
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Personalis, Inc. (NASDAQ:PSNL) Given Average Rating of “Moderate Buy” by Analysts
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of “Moderate Buy” by Brokerages
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 68,679 Personalis, Inc. $PSNL
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
Personalis Reports Third Quarter 2025 Financial Results
Personalis to Announce Third Quarter 2025 Financial Results
Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing